The Median Effective Volume of Ropivacaine for Obturator Nerve Block in Patients Undergoing Transurethral Resection of Bladder Tumor

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106391

Enrollment

Unknown

Registered

2025-07-23

Start date

2025-04-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Tumor

Interventions

Experimental group:Obturator nerve block with ropivacaine

Eligibility

Sex/Gender

All

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients scheduled for transurethral resection of bladder tumor (TURBT) with lateral wall bladder tumors; 2.Body mass index (BMI) ranging from 18.0 to 30.0 kg/m^2; 3.No gender restriction, aged between 50 and 90 years; 4.All enrolled patients classified as American Society of Anesthesiologists (ASA) physical status I to III; 5.Complete clinical data available.

Exclusion criteria

Exclusion criteria: 1.History of alcohol abuse, epilepsy, psychiatric disorders, or illicit drug use; 2.Patients with hearing impairment or aphasia; 3.Allergy to anesthetic agents used in this study; 4.History of bleeding disorders or coagulation abnormalities; 5.Contraindications to nerve blockade; 6.Severe organic diseases of the heart, liver, lungs, kidneys, or other major organs; 7.Pre-existing lower limb motor dysfunction or peripheral neurovascular disorders; 8.Patients who declined to participate.

Design outcomes

Primary

Measure	Time frame
Degree of adductor muscle strength reduction;	—

Secondary

Measure	Time frame
Intraoperative somatokinetic reaction;	—

Countries

China

Contacts

Public ContactZhao Ling

The First Affiliated Hospital of Xi'an Medical University

sisi79820@163.com+86 17791859818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026